- $13.19m
- -$52.32m
- $0.64m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.21 | ||
| Price to Tang. Book | 0.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.4% | ||
| Return on Equity | -68.85% | ||
| Operating Margin | -9863.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.64 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, is a C5-targeted Affibody molecule conjugated to polyethylene glycol; RLYB332, is a preclinical antibody designed to inhibit MTP-2, and REV102 Program, is a small molecule inhibitor of ectonucleotide pyrophosphatase/ phosphodiesterase 1(ENPP1).
Directors
- Martin Mackay CHM (65)
- Stephen Uden PRE (63)
- Jeffrey Fryer CFD (52)
- Steven Ryder OTH (70)
- Helen Boudreau IND (55)
- Robert Hopfner IND (49)
- Ronald Hunt IND (55)
- Lucian Iancovici IND (39)
- Kush Parmar IND (40)
- Timothy Shannon IND (62)
- Paula Soteropoulos IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 11th, 2020
- Public Since
- July 29th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 41,612,039
- Address
- 234 CHURCH STREET, SUITE 1020, NEW HAVEN, 06510
- Web
- https://rallybio.com/
- Phone
- +1 2038593820
- Contact
- Samantha Tracy
- Auditors
- Deloitte & Touche LLP
Upcoming Events for RLYB
Similar to RLYB
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 22:51 UTC, shares in Rallybio are trading at $0.32. This share price information is delayed by 15 minutes.
Shares in Rallybio last closed at $0.32 and the price had moved by -82.68% over the past 365 days. In terms of relative price strength the Rallybio share price has underperformed the S&P500 Index by -84.38% over the past year.
The overall consensus recommendation for Rallybio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRallybio does not currently pay a dividend.
Rallybio does not currently pay a dividend.
Rallybio does not currently pay a dividend.
To buy shares in Rallybio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.32, shares in Rallybio had a market capitalisation of $13.19m.
Here are the trading details for Rallybio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RLYB
Based on an overall assessment of its quality, value and momentum Rallybio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rallybio is $1.00. That is 215.46% above the last closing price of $0.32.
Analysts covering Rallybio currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rallybio. Over the past six months, its share price has underperformed the S&P500 Index by -68.47%.
As of the last closing price of $0.32, shares in Rallybio were trading -65.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rallybio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rallybio's management team is headed by:
- Martin Mackay - CHM
- Stephen Uden - PRE
- Jeffrey Fryer - CFD
- Steven Ryder - OTH
- Helen Boudreau - IND
- Robert Hopfner - IND
- Ronald Hunt - IND
- Lucian Iancovici - IND
- Kush Parmar - IND
- Timothy Shannon - IND
- Paula Soteropoulos - IND